
THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 308 Session of
2013

INTRODUCED BY TOOHL, COHEN, HENNESSEY, DIGIROLAMO, BAKER,
ROZZI, MIRABITO, KILLION, MILLARD, MAJOR, DONATUCCI, RAPP,
GROVE, READSHAW, GRELL, V. BROWN, YOUNGBLOOD, ROCK, KORTZ,
ROSS, BENNINGHOFF, HESS, GINGRICH, DENLINGER, FLECK, QUINN,
GILLEN, DEASY, BROOKS AND MAHONEY, MAY 8, 2013

INTRODUCED AS NONCONTROVERSIAL RESOLUTION UNDER RULE 35,
MAY 8, 2013

A RESOLUTION

1 Designating the month of June 2013 as "Cockayne Syndrome
2 Awareness Month" in Pennsylvania and commending the work of
3 the Share and Care Cockayne Syndrome Network for raising
4 awareness of this disease.

5 WHEREAS, Cockayne Syndrome, or CS, is a rare genetic disorder
6 affecting a small number of children worldwide, but its impact
7 on involved families is significant emotionally and
8 economically; and

9 WHEREAS, Edward Alfred Cockayne (1880-1956), after whom this
10 disease is named, was a London physician who concentrated
11 particularly on hereditary diseases of children; and

12 WHEREAS, CS is inherited in an autosomal recessive pattern;
13 therefore, in order for a child to be affected by CS, he or she
14 must inherit a mutation in the same CS gene from both parents;
15 and

16 WHEREAS, While parents, who are carriers of a single CS gene
17 mutation, remain healthy after the birth of a child with CS,

1 they have a one in four, or 25%, chance of having a second or
2 successive child with CS; and

3 WHEREAS, The symptoms of CS vary significantly, especially
4 with regard to the age of onset and rate of progression, and
5 include social, jovial personalities; sunburning easily;
6 progeria (premature aging); shortened life span; microcephaly;
7 neurodevelopment delay; short stature (height lower than the 5th
8 percentile for others in the age group); contractures; unsteady
9 gait; spasticity; rounded back; deep-set eyes and a small,
10 slender, straight nose; dental caries (cavities); retinopathy
11 and cataracts; hearing loss; poor circulation (cold hands and
12 feet); low body temperature; feeding problems; sleeping with
13 eyes open; tremors; white matter abnormalities; basal ganglia
14 calcifications; liver abnormalities; elevated liver enzymes;
15 hypertension; and severe itchiness; and

16 WHEREAS, The resulting spectrum of severity can be loosely
17 divided into three "types" of CS:

18 (1) CS Type I is characterized by normal prenatal growth
19 with the onset of growth and developmental abnormalities
20 around one year of age. The typical lifespan is 10 to 20
21 years of age.

22 (2) CS Type II is characterized by growth failure and
23 other abnormalities at birth, with little or no postnatal
24 neurological development. The typical lifespan is up to seven
25 years of age.

26 (3) CS Type III is characterized by a later onset,
27 lesser symptoms and a slower rate of progression. The
28 expected lifespan is unclear, but can extend to 40 or 50
29 years of age;

30 and

1 WHEREAS, Some individuals have combined features of CS and
2 Xeroderma Pigmentosum, which is characterized by a wide range of
3 skin changes from mild freckling to skin cancer on areas exposed
4 to sunlight; and

5 WHEREAS, No specific treatment currently exists for CS, and
6 patients are treated according to the symptoms they have, with
7 physical, occupational, speech, vision and hearing therapies
8 being beneficial; and

9 WHEREAS, It is important to those affected by CS to raise
10 awareness of this disease so that they find social and medical
11 support easily, and the Share and Care Cockayne Syndrome Network
12 provides information and support for those afflicted; therefore
13 be it

14 RESOLVED, That the House of Representatives designate the
15 month of June 2013 as "Cockayne Syndrome Awareness Month" in
16 Pennsylvania and commend the work of the Share and Care Cockayne
17 Syndrome Network for raising awareness of this disease.